Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16:667 671. 492. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111 493. Nu ez L, Gil Aguado M, Larrea JL, Celem n D, Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg. 1984;37:84 87. doi: 494. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-inten- sity oral anticoagulation alone: a randomized trial in patients with mechani- cal prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113:910 916. 495. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with war- farin after heart-valve replacement. N Engl J Med. 1993;329:524 529. 496. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D Avila A, Dobrev D, et al; Document Reviewers. EHRA/HRS/ APHRS/SOLAECE expert consensus on atrial cardiomyopathies: defini- tion, characterization, and clinical implication. Europace. 2016;18:1455 497. Guichard JB, Nattel S. Atrial cardiomyopathy: a useful notion in cardiac dis- ease management or a passing fad? J Am Coll Cardiol. 2017;70:756 765. CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 498. Iung B, Klein I, Mourvillier B, Olivot JM, D taint D, Longuet P, Ruimy R, Fourchy D, Laurichesse JJ, Laissy JP, et al; Study Group. Respective ef- fects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. 